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Abstract
Background: The available evidence on the benefits and harms of novel drugs and therapeutic biologics at the
time of approval is reported in publicly available documents provided by the US Food and Drug Administration
(FDA). We aimed to create a comprehensive database providing the relevant information required to systematically
analyze and assess this early evidence in meta-epidemiological research.
Methods: We designed a modular and flexible database of systematically collected data. We identified all novel
cancer drugs and therapeutic biologics approved by the FDA between 2000 and 2016, recorded regulatory
characteristics, acquired the corresponding FDA approval documents, identified all clinical trials reported therein,
and extracted trial design characteristics and treatment effects. Herein, we describe the rationale and design of the
data collection process, particularly the organization of the data capture, the identification and eligibility assessment
of clinical trials, and the data extraction activities.
Discussion: We established a comprehensive database on the comparative effects of drugs and therapeutic
biologics approved by the FDA over a time period of 17 years for the treatment of cancer (solid tumors and
hematological malignancies). The database provides information on the clinical trial evidence available at the time
of approval of novel cancer treatments. The modular nature and structure of the database and the data collection
processes allow updates, expansions, and adaption for a continuous meta-epidemiological analysis of novel drugs.
The database allows us to systematically evaluate benefits and harms of novel drugs and therapeutic biologics. It
provides a useful basis for meta-epidemiological research on the comparative effects of innovative cancer
treatments and continuous evaluations of regulatory developments.
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What is new
Key findings
We established a comprehensive database on novel
cancer drugs and therapeutic products approved by the
US Food and Drug Administration (FDA) between 2000
and 2016. The current database will be used to describe
the clinical trial evidence generated in the pre-marketing
period, but the database can and will be updated and
expanded for future meta-epidemiological analyses.
What this adds to what is known
Publicly available drug approval documents offer highly
valuable information that is very useful for evidence
syntheses and research-on-research projects. The
Comparative Effectiveness of Innovative Treatments for
Cancer (CEIT-Cancer) database transparently describes
and characterizes such information.
What is the implication, what should change now
This database allows systematic analysis and assessment
of early evidence on the benefits and harms of novel
drug treatments and provides a solid basis for continu-
ous meta-epidemiological analyses.
Background
Cancer drug development is characterized by a perceived
urgency to find novel treatments that improve patients’
survival and quality of life. Timely access to such benefi-
cial treatments is considered paramount for patients
with cancer. Before granting approval and market access,
health authorities such as the FDA review the available
evidence on benefits and harms from clinical trials and
the claims made by the pharmaceutical companies and
sponsors of the trials. The FDA examines the submitted
clinical trial results, re-analyzes the trial’s patient-level
data, and evaluates whether the trials were conducted
and analyzed in accordance with the original study
protocols [1, 2]. For drugs and therapeutic biologics that
receive approval, the FDA reviews are made publicly
available in the Drugs@FDA database as “approval
packages” [3]. These packages provide a wealth of
information on the evidence on benefits and harms of
innovative treatments at the time of approval.
With the introduction of new incentives and approval
pathways, the FDA aimed to facilitate the development
and approval process of drugs intended to treat serious
or life-threatening conditions, including cancer [4]. For
example, some policies focus specifically on orphan
drugs for rare diseases [4]. Between 2000 and 2012, 46
out of 47 oncology drugs approved by the FDA under-
went expedited approval [5]. In 2012, a further policy for
so-called “breakthrough” therapies was introduced for
drugs with highly promising clinical evidence [5].
However, there is increasing discussion about the
impact of these regulations because they may leave evi-
dence gaps regarding efficacy and safety and increase
uncertainty in clinical decision making as expedited and
orphan drug approvals are often based on smaller
studies than used in traditional approvals [6]. At the
time of approval, there may be a dearth of evidence on
hard clinical outcomes and subsequent follow-up evalua-
tions suggest that such evidence either may never
become available or may end up showing limited or no
benefits [7–9]. Oncology and hematology are probably
the medical fields which are currently most affected by
such developments.
Numerous meta-epidemiological studies aimed to
better understand the evidence at the time of approval
of novel cancer drugs and therapeutic biologics using
data from the FDA and the European Medicines Agency
(EMA). We give an overview of these studies and the re-
search in context in Table 1 (details of the underlying
search strategy are provided in Additional file 1). The
first related investigation that we are aware of was pub-
lished in 2009 [10], and the number of publications
peaked in 2017 with 10 articles. Nonetheless, a major
limitation is that many of these studies cover only cer-
tain types of cancer (for example, solid tumors). Overall,
there are four studies [10–13] which describe regulatory
characteristics and clinical trials and assess endpoints
and effect sizes used for approval on all cancer drugs,
but none of them covers the most recently approved
drugs (for example, after 2013). This would not allow
the assessment of newer policies such as the break-
through program introduced in 2012. Thus, the current
knowledge on approval evidence for cancer drugs is
marked by not only a limited scope but also a great
diversity in methods and approaches, reducing the inter-
pretability of the findings.
To address such limitations, we intended to establish a
comprehensive database allowing a continuous analysis of
such regulatory developments in meta-epidemiological
research. The ongoing “Comparative Effectiveness of
Innovative Treatments for Cancer” (CEIT-Cancer) project
aims to transparently describe and characterize the clinical
trial evidence of novel cancer drugs. Our goal is to capture
the relevant information required to systematically analyze
and assess early evidence on benefits and harms of novel
cancer drug treatments.
As a first step, we collected the pre-marketing clinical
trial evidence using FDA approval documents with a
specific focus on cancer drugs, randomized controlled
trials (RCTs) and single-arm trials (SATs), and treatment
effects on overall survival (OS), progression-free survival
(PFS), and objective response rate (RR). However, the
overall database structure is organized in a modular
nature which allows continuous updating of the list of
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drugs, the addition of new variables, expansion of the
number of topics, health authorities, and outcomes as
well as linkage with other related datasets (for example,
from post-approval evidence including non-randomized
real-world studies).
Herein, we describe the rationale and design of the
data collection process for the pre-approval evidence, in-
cluding the organization of the data capture, the identifi-
cation of clinical trial information, the assessment of
trials for eligibility, and the data extraction.
Methods
Data collection
Project organization and database structure
The data collection consisted of three steps. In step 1,
we made an inventory of novel FDA-approved drug
products and acquired the corresponding FDA approval
packages. In step 2, we made an inventory of RCTs and
SATs reported in FDA approval documents, assessed
their eligibility, and extracted trial design characteristics.
In step 3, we extracted treatment effects on OS, PFS,
and RR.
Steps 2 and 3 started with a planning and organizing
phase (operationalization of concepts, drafting of an
instruction manual for standardized data selection and
extraction, setting up the extraction platform, pilot test-
ing of the instruction manual and extraction platform,
and training of reviewers) followed by an execution
phase (independent data extraction and verification) and
ended with a closing phase (documentation of activities).
Specific project activities are described in greater detail
in the following sections.
The clinical trial data were managed in a single data-
base. The database consists of four data tables (with in-
formation about the drug, indication, trial, study groups
and treatment comparisons, and treatment effects) that
are linked in one-to-many (1:n) relationships (Fig. 1).
The relational structure is indispensable because of the
nature of the data (for example, multiple indications ap-
proved for a single drug, multiple clinical trials supporting
approval of a single indication, and multiple comparisons
within a single multi-arm clinical trial). We used both
Microsoft Access as a local data extraction and manage-
ment platform and Ragic [14] as a cloud-based equivalent.
Step 1: Inventory of FDA-approved drugs and acquisition of
approval packages
The aims of this step were to identify and characterize
all drugs licensed by the FDA for the treatment of
cancer diseases and to download as well as prepare FDA
approval documents for subsequent activities. This step
was performed by a single reviewer (AL).
Inventory of FDA-approved drugs
In a first stage, we created a list of novel drugs and thera-
peutic biologics (referred to in this article as “drugs”) that
were granted their first FDA marketing authorization be-
tween 1 January 2000 and 31 December 2016. (Technic-
ally speaking, we included so-called “new molecular
entities” and “new therapeutic biologics” approved via
either a “New Drug Application” or a “Biologics License
Application”.) The drug names were collected from the
“Annual drug and biologic approval activity” reports for
new molecular and biological entities (2000 to 2016) [15]
as well as the “FDA reports on drug innovation” (2011 to
2016) [16]. Information on therapeutic biologics approved
before 2004 is not available in these documents and there-
fore we reviewed the drug approval reports by month for
the period of January 2000 to December 2003 obtained
from the Drugs@FDA database [3].
Selection of cancer indications
In a second stage, drugs were considered for inclusion in
the CEIT-Cancer database if the original approval (that
is, the first-ever approved use of a novel drug) was for
the treatment of a solid tumor or hematological malig-
nancy. Drugs without presumed cancer activity, such as
supportive care drugs (for example, anti-emetics and
hematopoietic stem cell mobilizing agents) or imaging
drugs (for example, diagnostic radiopharmaceutical
agents), were excluded. A medical oncologist (BK) was
consulted in case of any doubts about eligibility.
Extraction of information on drug, indication, and
regulatory characteristics
In the third stage, we collated information on drug,
indication, and regulatory characteristics for each eligible
drug and cancer indication (“drug-indication pair”;
Table 2). The line of treatment was determined by a
medical oncologist (BK). The remaining information was
retrieved from various information sources as follows.
For drug-indication pair characteristics:
 “Annual drug and biologic approval activity” reports
for new molecular and biological entities (2000 to
2016) [3], “FDA reports on drug innovation” (2011
to 2016) [16], and a peer-reviewed publication [17]
for drug and regulatory characteristics, and
 the first-ever available FDA drug label from the
Drugs@FDA database [3] for information about the
FDA-approved indication(s).
For information on additional expedited programs and
orphan status, we perused the following:
 “FDA reports on accelerated approvals” to identify
accelerated approved indications [18]; that is,
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indications approved on the basis of preliminary
evidence that does not meet regulatory standards for
traditional (full) approval [4];
 “Breakthrough designation approval” reports [19] to
identify indications that received a breakthrough
therapy designation in the pre-approval period; that
is, drugs that are expected to advance the treatment
of certain diseases [4]; and
 FDA database of orphan drug product designations
to identify indications that received an orphan status
[20]; that is, drugs intended for the treatment of rare
diseases affecting fewer than 200,000 people in the
US [21].
All documents were downloaded or accessed on 2
November 2015 (for the 2000 to 2012 approvals) and 2
March 2017 (for the 2013 to 2016 approvals). We relied
on the information from the Drugs@FDA database in
the case of discrepant information between information
sources (for example, if there were different approval dates
presented). We categorized the drug innovation class
(first-in-class, advance-in-class, and addition-to-class) in
accordance with the algorithm of Lanthier et al. [17].
Accordingly, first-in-class drugs can be seen as “true”
therapeutic innovation and define a new drug class.
Advance-in-class drugs may offer an important thera-
peutic advance (that is, they were granted priority review
by the FDA) over existing drugs in the same class. Drugs
that do not fall under either of these two categories are
categorized as addition-to-class.
Approval packages
The FDA’s review of the pre-clinical and clinical infor-
mation generated by a biopharmaceutical company
during the course of drug development is summarized
in FDA “approval packages” published in the
Drugs@FDA database. We used a similar approach to
retrieve the approval documents as described recently
[22], and we provided practical details on how we
navigated the documents elsewhere [23]. The following
documents served as source documents throughout this
project and were made suitable for text searching using
Adobe Acrobat’s Optical Character Recognition (OCR)
function:
 Medical review (sometimes referred to as clinical
review)
 Statistical review
 Drug label
 Cross-discipline team leader review
 Summary review
 Multi-discipline review.
Step 2: Trial selection and characterization
The aims of this step were to identify eligible clinical
trials in the medical review, assess their eligibility, and
characterize their design characteristics. These activities
were performed by teams of two independent reviewers.
Trials include randomized and non-randomized studies
(the latter within the category of SATs), and for each
trial the database explicitly indicates whether a random-
ized design was used.
Identification of trials, eligibility assessment, and data
extraction
Each reviewer was provided with a set of indications
to identify potentially eligible trials. Reviewers inde-
pendently searched the medical review document for
Fig. 1 Database structure used in the Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project for data collection
and management
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randomized trials as well as for trials that were indi-
cated as pivotal for approval (that is, the trial was de-
scribed as “approval”, “registration”, “major”, “pivotal”,
or similar) regardless of whether they were random-
ized or not. For each trial, the reviewers recorded
variables presented in Table 3. In particular, they ex-
tracted the study identifier, name, or acronym and
determined whether the following criteria were met
(each criterion was assessed separately):
(1) the trial was explicitly described as pivotal to
approval,
(2) the patients were randomly assigned to treatment
arms,
Table 2 Variables collected in step 1 for each cancer drug-indication pair
Variable (Data type), data value or code Description and further elaboration
Drug characteristics
Brand name (Character string) As accepted by the US Food and Drug Administration
(FDA) and used in the US.
Generic name (Character string) According to US Adopted Names.
Type of active compound “NME”; “NBE” NME (New Molecular Entity, that is, a small molecule) or
NBE (New Biologic Entity; that is, a biologic product).
Date of marketing authorization (Date) Format: YYYY-MM-DD.
Innovation class “First-in-class”; “Advance-in-class”;
“Addition-to-class”
Drug innovation class, following the definitions and
categories described by Lanthier et al. [17]. New molecular
or new biological entities are categorized as “First-in-class”
if they define a new drug class, as “Advance-in-class” if they
offer significant therapeutic advance (that is, they were
granted priority review by the FDA) over existing drugs in
the same class, or “Addition-to-class” in any other case.
Indication characteristics
FDA-approved indication (Character string) Medical condition for which the drug of interest has been
approved, according to the first-ever available FDA drug
label.
Line of treatment “1st”; “2nd”; “3rd”; “4th” The clinical order the treatment is given
NDA/BLA number (Integer) FDA’s Original New Drug Application (NDA) or Biologics
License Application (BLA) number. A unique identifier
assigned to each application for approval submitted to the
FDA.
Site of disease “Breast”; “Digestive”; “Gastrointestinal”;
“Endocrine and Neuroendocrine”;
“Genitourinary”; “Gynecologic”; “Leukemia”;
“Lymphoma”; “Musculoskeletal”; “Neurologic”;
“Other - Multicentric Castleman’s Disease”;
“Other - Other”; “T-cell malignancies”;
“Respiratory/Thoracic”; “Skin”
Cancers by body location/system (following the
classification by the National Cancer Institute
(www.cancer.gov/types/by-body-location).
Regulatory characteristics
Priority review “Standard”; “Priority” Priority review is an expedited FDA review program for
drugs that provide a significant improvement over existing
therapies.
Accelerated approval “Yes”; “No” Expedited FDA approval pathway for drugs that (a) treat
serious conditions, (b) provide a meaningful advantage
over available therapies, and (c) demonstrate effects on a
surrogate endpoint that is reasonably likely to predict
clinical endpoints. Accelerated approved drugs do not
meet regulatory standards for traditional or full approval
and are therefore required to provide evidence of clinical
benefit in subsequent pivotal trials.
Breakthrough therapy designation “Yes”; “No” An expedited program at FDA introduced in 2012 for
drugs that are (a) intended to treat serious conditions and
(b) provide preliminary clinical evidence of substantial
improvement over existing therapies.
Orphan designation “Yes”; “No” A status assigned by the FDA to rare disease indications if
less than 200,000 people in the US are affected.
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(3) the patients matched broadly in their disease
characteristics with the approved target
population,
(4) the patients were randomly assigned to at least one
control arm that did not contain the drug under
review (regardless of dose or administration
schedule),
(5) as per the judgment of the reviewer, a trial
could still be relevant even if none of the
abovementioned criteria was met; for example, if
the trial is extensively discussed or the only
trial evaluated in the medical review (which is
sometimes the case in accelerated approval
settings, where such trials are often not explicitly
labeled as “pivotal” but extensively discussed in
the documents).
After completion, the two independently generated
datasets were compared and disagreements resolved
by consensus. The inter-rater reliability for trial iden-
tification (as assessed with the Kappa statistic [24])
was good (74%). Ultimately, trials that met any of the
following sets of criteria were deemed eligible:
 the trial was described as pivotal (criterion 1 alone is
met; categorized as “explicitly pivotal”)
 the trial was not described as pivotal but was
randomized (criterion 2), enrolled a population that
matched the approved target population (criterion
3), and had a control arm that did not contain the
intervention under review (criterion 4) (categorized
as “likely pivotal RCT”)
 the trial was not “explicitly pivotal” or a “likely
pivotal RCT” but considered otherwise essential
(criterion 5) for the approval decision (categorized
as “other pivotal”). Such trials were typically single-
arm studies in accelerated approval settings.
For each eligible trial, teams of two independent
reviewers extracted information on variables presented
in Table 4.
Step 3: Treatment effect estimates on overall survival,
progression-free survival, and response rate
The aim of this step was to retrieve treatment effect esti-
mates on OS, PFS, and RR for each treatment compari-
son. This information was collected only for RCTs. This
activity was performed by teams of two independent
reviewers.
Data extraction
We preferred trial analyses conducted by the FDA over
sponsors’ analyses, whenever both were available. Simi-
larly, more recent data cutoff dates were preferred over
older cutoff dates if there were multiple analysis results
on the same endpoint available. We used the statistical
review document (or any other FDA approval docu-
ments) if the medical review document was not available
or was incomplete or not legible.
For each treatment comparison, two reviewers inde-
pendently searched the FDA review documents for treat-
ment effect estimates on OS, PFS, and RR and extracted
information on variables presented in Table 5. For OS and
PFS endpoints with incomplete or missing information
Table 3 Variables collected in step 2 for trials that were randomized or explicitly labeled as pivotal
Variable (Data type), data value or code Description and further elaboration
Trial characteristics (for any trial identified in step 2)
Trial name reference (Character string) Reference trial name.
Trial name 1 (Character string) Alternative trial name 1.
Trial name 2 (Character string) Alternative trial name 2.
Pivotal “Yes”; “No” Trial eligibility criteria: the trial is described as “pivotal”
(or similar).
Randomized “Yes”; “No”; “Single-arm” Trial eligibility criteria: patients are randomly assigned
to treatment arms.
On-label “Yes”; “No”; “Partially”; “Not reported” Trial eligibility criteria: the drug of interest is tested in
the approved indication.
Comparator “Yes”; “No”; “Partially”; “Not reported” Trial eligibility criteria: the control intervention does not
contain the active component of the drug under
review.
Relevance “Yes”; “No” Trial eligibility criteria: two reviewers consider that this
trial was definitely used for approval, but none of the
abovementioned eligibility criteria are met.
Eligible rationale “explicitly pivotal”; “likely pivotal”; “other pivotal”;
“not eligible”
The rationale for trial eligibility based on eligibility
algorithm.
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(for example, no confidence interval), we approximated
treatment effect estimates following the methods
described by Parmar et al. [25] and Tierney et al. [26]. At
the end of the data collection activities in this step, the
datasets of the two reviewers evaluating the same set of
treatment comparisons were compared, and disagree-
ments were resolved by consensus.
Discussion
We have successfully developed the CEIT-Cancer
database, which transparently describes and character-
izes information on the clinical trial evidence of novel
cancer drugs at the time of their approval by the FDA.
Exploring characteristics of the evidence of novel
cancer drugs at the time of their approval could greatly
improve our understanding of the real-world clinical
benefit and safety of such treatments. Importantly, it
may also open new avenues of future research and regu-
lation, leading to better-designed studies, reduced waste
in research, and more rigorous criteria for health author-
ities and health systems to consider incorporating new
interventions into the current cancer armamentarium.
The CEIT-Cancer database is a comprehensive, manu-
ally curated platform that captures regulatory, drug,
indication, and clinical trial data from FDA approvals of
novel cancer drugs. This database differs from previous
investigations in three important ways. First, the
CEIT-Cancer database covers a time frame of 17 years,
substantially larger compared with most previous studies.
Second, it assesses all types of cancers, including both
solid tumors and hematologic malignancies. Third,
the database encompasses the most recent FDA drug
approvals. In addition, this database can be expanded
to other medical fields and be linked with other
databases. It can be augmented with post-approval
evidence and also can be expanded for data extraction
of approval documents from other health authorities,
such as the EMA [11, 27].
We have set up the database and realized the project
in a multidisciplinary team including experts in clinical
trial methodology and conduct, clinical epidemiology,
health technology assessment, biostatistics, clinical re-
search, information management, public health, and
medical oncology. The initial dataset covers a time
period of 17 years. This allows us to investigate several
regulatory developments over time and changes in the
focus of drug development, such as the development of
targeted agents and immunotherapy in contrast to clas-
sic cytotoxic chemotherapy. Following standardized and
established data extraction procedures as in systematic
reviews, we created a large evidence base on treatment
effects and trial quality. This lays the foundation for our
Table 4 Variables collected in step 2 for eligible trials only
Variable (Data type), data value or code Description and further elaboration
Trial characteristics (for any trial deemed eligible in step 2)
Randomization “Yes”; “No” Random allocation of patients to trial arms
N arms (Integer) The number of trial arms.
Other trial characteristics “Parallel”; “Cross-over”;
“Uncontrolled/historic control”
Patients are randomized to a concurrent control
(“Parallel”) or to a sequence of treatments (“Cross-over”).
Comparison characteristics
Arm 1
Type “Experimental”; “Active”; “Placebo”;
“No treatment”; “Dose-comparison”
In add-on trials, comparators were categorized as
“active” whenever an intervention given on top of an
active treatment (for example, standard of care with or
without placebo). Comparators were categorized as
“No treatment” if “supportive therapy” or “usual care”
was given which included a wide variety of treatments
rather than a specific intervention.
Characteristics (Character string) All interventions in arm 1, including drug names, doses,
and route of administration. Interventions used to avoid
treatment-related complications were not recorded,
such as pre-treatment with acetaminophen/diphen-
hydramine to reduce infusion reactions with
intravenous infusion of therapeutic biologics, or
anti-emetics to reduce nausea and vomiting associated
with certain chemotherapies.
Arm 2
Type “Active”; “Placebo”; “No treatment”;
“Dose-comparison”; “Uncontrolled/historic
control”
See “Arm 1” above.
Characteristics (Character string) See “Arm 1” above.
Ladanie et al. Trials  (2018) 19:505 Page 9 of 13
Table 5 Variables collected in step 3 for eligible randomized controlled trials retrieved on comparison level
Variable (Data type), data value or code Description and further elaboration
Overall survival OR progression-free survival
Is the endpoint reported “Yes”; “No” .
Response criteria (Character string) Progression-free survival only: response criteria used to
measure response to treatment
Number of patients in arm 1 (Integer) Number of patients in arm 1 included in the endpoint
analysis
Number of patients in arm 2 (Integer) Number of patients in arm 2 included in the endpoint
analysis
Number of events in arm 1 (Integer) Number of patients with events in arm 1 included in the
endpoint analysis
Number of events in arm 2 (Integer) Number of patients with events in arm 2 included in the
endpoint analysis
Hazard ratio: coverage probability (Float) Confidence level (1-alpha) in the endpoint analysis
Hazard ratio: point estimate (Float) Hazard ratio point estimate (selection rule: primary analysis
according to the US Food and Drug Administration, but
longest follow-up)
Hazard ratio: lower confidence
bound
(Float) The lower bound of the confidence interval of the hazard
ratio estimate
Hazard ratio: upper confidence
bound
(Float) The upper bound of the confidence interval of the hazard
ratio estimate
Randomization ratio “1:1”; “Not 1:1” Randomization ratio, extracted for incomplete endpoint
effects to derive appropriate statistics [25, 26]
Regression P value (Float) Regression P value of the endpoint effect, extracted for
incomplete endpoint effects to derive appropriate statistics
[25, 26]
Test type “1-sided”; “2-sided”;
“Not reported”
One- or two-sided P value, extracted for incomplete
endpoint effects to derive appropriate statistics [25, 26]
Hazard rate in arm 1 (Float) Hazard rate in arm 1, extracted for incomplete endpoint
effects to derive appropriate statistics [25, 26]
Hazard rate in arm 2 (Float) Hazard rate in arm 2, extracted for incomplete endpoint
effects to derive appropriate statistics [25, 26]
Logrank observed minus expected
events in arm 1
(Integer) Logrank Observed minus Expected (O-E) events in arm 1
(endpoint analysis), extracted for incomplete endpoint
effects to derive appropriate statistics [25, 26]
Logrank observed minus expected
events in arm 2
(Integer) Logrank Observed minus Expected (O-E) events in arm 2
(endpoint analysis), extracted for incomplete endpoint
effects to derive appropriate statistics [25, 26]
Logrank variance (Float) Logrank variance (endpoint analysis), extracted for
incomplete endpoint effects to derive appropriate
statistics [25, 26]
Median survival time in arm 1:
point estimate
(Float) Median survival time (point estimate) in arm 1
Median survival time in arm 1:
lower confidence bound
(Float) The lower bound of the confidence interval of the median
survival time in arm 1
Median survival time in arm 1:
upper confidence bound
(Float) The upper bound of the confidence interval of the median
survival time in arm 1
Median survival time in arm 2 (Float) Median survival time (point estimate) in arm 2
Median survival time in arm 2:
lower confidence bound
(Float) Lower bound of the confidence interval of the median
survival time in arm 2
Median survival time in arm 2:
upper confidence bound
(Float) Upper bound of the confidence interval of the median
survival time in arm 2
Time unit “Days”; “Weeks”; “Months”;
“Years”; “Not reported”
Time unit used to measure median survival improvement
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planned continuous meta-epidemiological analysis of
novel drugs and therapeutic biologics within the
CEIT-Cancer project. We are currently developing the
infrastructure to make the database available and aim to
obtain structural funding and support to provide a
sustainable solution. Through the collaborating partici-
pation of other investigators, we aim to establish a
data-sharing process to provide access to the database
and foster further research.
Conclusions
Publicly available drug approval documents offer highly
valuable information that is very useful for evidence
syntheses and research-on-research projects. The
CEIT-Cancer database transparently describes and char-
acterizes this information on the clinical trial evidence
of novel cancer drugs. It allows systematic analysis and
assessment of early evidence on benefits and harms of
novel drug treatments in meta-epidemiological research.
The modular nature and structure of the database as
well as the data collection processes permit continuous
updates and expansions. Overall, the database provides a
solid basis for meta-epidemiological research of the evi-
dence on novel treatments in cancer.
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tumor response endpoint analysis
Number of events in arm 2 (Integer) Number of patients with events in arm 2 included in the
tumor response endpoint analysis
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